New drug duo aims to stall aggressive lung cancer after chemo
NCT ID NCT06497530
First seen Jun 10, 2026 · Last updated Jun 19, 2026 · Updated 1 time
Summary
This study tests whether a combination of two drugs, lurbinectedin and serplulimab, can help keep extensive-stage small cell lung cancer from growing after initial chemotherapy. About 30 adults whose cancer has not worsened after four cycles of standard chemo will receive the drug combo as maintenance therapy. The main goal is to see how long the cancer stays under control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The first affiliated hospital of Guangzhou medical university
RECRUITINGGuangzhou, Guangdong, 51000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lurbinectedin and serplulimab (drug combination)
What this could lead to
If successful, this could offer a new maintenance option to help keep extensive-stage small cell lung cancer from progressing after initial chemotherapy.
What could go wrong
This is a small, early-phase exploratory study with only 30 participants, so results may not apply broadly. The combination may cause side effects or fail to improve outcomes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.